Our analysis of drug‒gene interactions revealed that drugs such as linifanib, sorafenib, sunitinib, and midostaurin have the potential to target HOXA9 in cancer, thereby increasing chemosensitivity in cancer cells. The gene discussed is HOXA9; the disease is cancer.